NO20002639L - Inhibering av lipoproteinoksidering - Google Patents
Inhibering av lipoproteinoksideringInfo
- Publication number
- NO20002639L NO20002639L NO20002639A NO20002639A NO20002639L NO 20002639 L NO20002639 L NO 20002639L NO 20002639 A NO20002639 A NO 20002639A NO 20002639 A NO20002639 A NO 20002639A NO 20002639 L NO20002639 L NO 20002639L
- Authority
- NO
- Norway
- Prior art keywords
- inhibition
- lipoprotein oxidation
- lipoprotein
- oxidation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6688897P | 1997-11-25 | 1997-11-25 | |
| PCT/US1998/023483 WO1999026583A2 (en) | 1997-11-25 | 1998-11-04 | Inhibtion of lipoprotein oxidation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20002639L true NO20002639L (no) | 2000-05-23 |
| NO20002639D0 NO20002639D0 (no) | 2000-05-23 |
Family
ID=22072341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20002639A NO20002639D0 (no) | 1997-11-25 | 2000-05-23 | Inhibering av lipoproteinoksidering |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6362236B1 (xx) |
| EP (1) | EP1047421A2 (xx) |
| JP (1) | JP2001523694A (xx) |
| KR (3) | KR100539644B1 (xx) |
| CN (1) | CN1160068C (xx) |
| AR (1) | AR015487A1 (xx) |
| AU (1) | AU759376B2 (xx) |
| BR (1) | BR9815039A (xx) |
| CA (1) | CA2303864A1 (xx) |
| CO (1) | CO4970835A1 (xx) |
| HK (1) | HK1033095A1 (xx) |
| HU (1) | HUP0004396A3 (xx) |
| IL (1) | IL135154A (xx) |
| IS (1) | IS5413A (xx) |
| NO (1) | NO20002639D0 (xx) |
| NZ (1) | NZ503598A (xx) |
| PE (1) | PE134199A1 (xx) |
| PL (1) | PL341397A1 (xx) |
| TR (1) | TR200001522T2 (xx) |
| TW (1) | TW552137B (xx) |
| UY (1) | UY25268A1 (xx) |
| WO (1) | WO1999026583A2 (xx) |
| ZA (1) | ZA9810743B (xx) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7250304B2 (en) * | 2000-03-31 | 2007-07-31 | The Regents Of The University Of California | Functional assay of high-density lipoprotein |
| US20030040505A1 (en) * | 2000-03-31 | 2003-02-27 | The Regents Of The University Of California | Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions |
| PE20030324A1 (es) * | 2001-07-31 | 2003-04-03 | Warner Lambert Co | Composiciones farmaceuticas de amlodipina y atorvastatina |
| MXPA05007674A (es) | 2003-01-23 | 2005-09-22 | Esperion Therapeutics Inc | Compuestos de hidroxilo y composiciones para el manejo del colesterol y usos relacionados. |
| US20060194981A1 (en) * | 2005-02-26 | 2006-08-31 | Jass Paul A | Process for preparation of probucol derivatives |
| WO2006104399A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Copper antagonist compositions |
| EP3578177A1 (en) | 2008-09-02 | 2019-12-11 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| BRPI1011876B1 (pt) | 2009-04-29 | 2020-03-31 | Amarin Pharma, Inc. | Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular |
| NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| CN102625847A (zh) | 2009-06-15 | 2012-08-01 | 阿马里纳制药公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法 |
| AU2010298222B2 (en) | 2009-09-23 | 2017-01-05 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| AU2011336856A1 (en) | 2010-11-29 | 2013-07-04 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
| SG10201913645RA (en) | 2012-06-29 | 2020-03-30 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| KR101665180B1 (ko) | 2014-07-01 | 2016-10-14 | 순천향대학교 산학협력단 | 아포지단백질 a-i 돌연변이체 g59v를 포함하는 항산화성 펩타이드 및 이를 포함하는 항산화 조성물 |
| CN107530307A (zh) | 2015-03-13 | 2018-01-02 | 艾斯柏伦治疗公司 | 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法 |
| MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| MA51765A (fr) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
| EP3986860A1 (en) | 2019-06-21 | 2022-04-27 | Esperion Therapeutics, Inc. | Salt forms of bempedoic acid and methods for using the same |
| US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
-
1998
- 1998-11-04 CA CA002303864A patent/CA2303864A1/en not_active Abandoned
- 1998-11-04 IL IL13515498A patent/IL135154A/xx not_active IP Right Cessation
- 1998-11-04 US US09/485,250 patent/US6362236B1/en not_active Expired - Fee Related
- 1998-11-04 BR BR9815039-1A patent/BR9815039A/pt not_active Application Discontinuation
- 1998-11-04 CN CNB988112671A patent/CN1160068C/zh not_active Expired - Fee Related
- 1998-11-04 KR KR10-2000-7005641A patent/KR100539644B1/ko not_active IP Right Cessation
- 1998-11-04 HU HU0004396A patent/HUP0004396A3/hu unknown
- 1998-11-04 EP EP98959378A patent/EP1047421A2/en not_active Withdrawn
- 1998-11-04 KR KR1020057014824A patent/KR20050086975A/ko not_active Application Discontinuation
- 1998-11-04 NZ NZ503598A patent/NZ503598A/en unknown
- 1998-11-04 JP JP2000521788A patent/JP2001523694A/ja not_active Abandoned
- 1998-11-04 KR KR1020057021847A patent/KR100586754B1/ko not_active IP Right Cessation
- 1998-11-04 PL PL98341397A patent/PL341397A1/xx not_active Application Discontinuation
- 1998-11-04 TR TR2000/01522T patent/TR200001522T2/xx unknown
- 1998-11-04 WO PCT/US1998/023483 patent/WO1999026583A2/en not_active Application Discontinuation
- 1998-11-04 AU AU15188/99A patent/AU759376B2/en not_active Ceased
- 1998-11-24 UY UY25268A patent/UY25268A1/es not_active Application Discontinuation
- 1998-11-24 PE PE1998001143A patent/PE134199A1/es not_active Application Discontinuation
- 1998-11-24 ZA ZA9810743A patent/ZA9810743B/xx unknown
- 1998-11-24 AR ARP980105959A patent/AR015487A1/es unknown
- 1998-11-24 CO CO98069227A patent/CO4970835A1/es unknown
- 1998-11-25 TW TW087119590A patent/TW552137B/zh not_active IP Right Cessation
-
2000
- 2000-03-24 IS IS5413A patent/IS5413A/is unknown
- 2000-05-23 NO NO20002639A patent/NO20002639D0/no unknown
-
2001
- 2001-06-04 HK HK01103822A patent/HK1033095A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20002639D0 (no) | 2000-05-23 |
| IL135154A (en) | 2005-05-17 |
| WO1999026583A2 (en) | 1999-06-03 |
| TR200001522T2 (tr) | 2000-12-21 |
| HUP0004396A3 (en) | 2003-04-28 |
| IS5413A (is) | 2000-03-24 |
| AR015487A1 (es) | 2001-05-02 |
| BR9815039A (pt) | 2001-03-20 |
| HUP0004396A2 (hu) | 2001-06-28 |
| KR100586754B1 (ko) | 2006-06-08 |
| CO4970835A1 (es) | 2000-11-07 |
| KR20010032401A (ko) | 2001-04-16 |
| PL341397A1 (en) | 2001-04-09 |
| EP1047421A2 (en) | 2000-11-02 |
| TW552137B (en) | 2003-09-11 |
| KR20050086975A (ko) | 2005-08-30 |
| AU759376B2 (en) | 2003-04-10 |
| ZA9810743B (en) | 1999-05-31 |
| WO1999026583A3 (en) | 1999-12-09 |
| KR20050113288A (ko) | 2005-12-01 |
| NZ503598A (en) | 2002-06-28 |
| PE134199A1 (es) | 2000-01-20 |
| UY25268A1 (es) | 1999-07-19 |
| IL135154A0 (en) | 2001-05-20 |
| HK1033095A1 (en) | 2001-08-17 |
| AU1518899A (en) | 1999-06-15 |
| CA2303864A1 (en) | 1999-06-03 |
| CN1160068C (zh) | 2004-08-04 |
| JP2001523694A (ja) | 2001-11-27 |
| US6362236B1 (en) | 2002-03-26 |
| KR100539644B1 (ko) | 2005-12-29 |
| CN1279605A (zh) | 2001-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20002639D0 (no) | Inhibering av lipoproteinoksidering | |
| CY2012029I2 (el) | Nεα μορφη της 5-ομεπραζολης | |
| FI973596A0 (fi) | Identifikation av talaktiviteten av en kaella | |
| ID24638A (id) | Senyawa-senyawa anti aritmia bispidina | |
| ID18406A (id) | Palang penggantung pakaian | |
| NO20004217D0 (no) | Inhibitorer av fosfolipase A2 | |
| DE69721533D1 (de) | Bekleidungsstück | |
| NO951287L (no) | Estimering av eksitasjonsparametere | |
| NO993717D0 (no) | Anvendelse av gastrointestinale lipase-inhibitorer | |
| DE69907146D1 (de) | Direkte oxidation von cycloalkanen | |
| FI980387A0 (fi) | Foerfarande foer att foerhindra bildning av utfaellningar i svartlutsindunstare | |
| NO20011491D0 (no) | Reduksjon av oksidative stress faktorer | |
| NO996545D0 (no) | Behandling av aluminiumslagg | |
| ID24270A (id) | Penghilang sumbatan keratotik | |
| ID28032A (id) | TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2 | |
| NO990832D0 (no) | Syntese av bisendolylmalimider | |
| FI964570A (fi) | Puheluiden yhdistäminen | |
| ID23437A (id) | Penghilang sumbatan keratotik | |
| NO993549D0 (no) | Imino-aza-antracyklinonderivater til behandling av amyloidosis | |
| FI942576A0 (fi) | Behandling av plasma | |
| DE69811256D1 (de) | Polymorphe modifikationen von dofetilid | |
| NO991148D0 (no) | Fremstilling av 1-butyl-4-piperidinyl-metylamin | |
| NO20000274D0 (no) | Behandling av fluider | |
| ID24344A (id) | Pemurnian propilena oksida | |
| IS4339A (is) | Hömlun ljóssundurliðunar á 3-setnum-2-oxindólum |